Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision

Forest Laboratories and H. Lundbeck A/S of Denmark said that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 13, 2006 decision by the U.S. District Court for the District of Delaware which determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro, is valid and upheld the injunction preventing Ivax/Teva’s proposed generic product launch, thereby confirming Forest’s and Lundbeck’s patent rights for Lexapro, which expire in March 2012.
Forest Laboratories